Compugen opened lower at $2.04, compared with its previous close of $2.09. In the last trading session, the stock traded between $2.04 and $2.14. It showed an upward intraday trend.
An investment of $100 made 5 years ago in Compugen is now worth
$ 29.55
Resulting in a loss of
$ 70.45 (70.45%)
Note: Past profits do not guarantee future returns.
Rating from 4 Analysts
Today's Change
+$0.03 (+1.24%)
Day High
$2.14
Day Low
$2.04
Day Open
$2.04
Prev Close
$2.09
Volume
1,83,451
1W Return
3.98%
1M Return
1.98%
3M Return
-12.02%
6M Return
-26.27%
1Y Return
23.02%
Market Cap ($ Mn)
200
PE Ratio
6.87
PB Ratio
2.79
PEG Ratio
-
ROE
57.22%
ROCE
32.35%
EPS (TTM)
$-0.07
1 Week
3.98%
1 Month
1.98%
3 Months
-12.02%
6 Months
-26.27%
9 Months
23.74%
Compugen Q3 Results: Sales jump 102% YoY to $3.821 million
Revenue rose 102.06% YoY to $3.821 million. Quarterly loss narrowed to $(0.06) per share from $(0.07). Sales exceeded analyst estimates by 124.76%. EPS beat consensus estimate of $(0.08) by 25%.
3 days agoCompugen to release Q3FY26 results on November 9, 2026
Compugen releases Q3 2026 results on November 9, 2026. Conference call scheduled for 8:30 am ET same day. Pipeline includes COM701, rilvegostomig, and GS-0321.
17 days agoCompugen Q2 Results: Revenue doubles, net loss narrows to $7M
Compugen Ltd. reported Q2 2026 revenues of $2.6 million, double the prior year figure, driven by Gilead milestone payments. Net loss narrowed to $7.0 million ($0.07/share) from $7.3 million. Cash reserves of $125.3 million fund operations into 2029. Pipeline updates include COM701 interim data expected in Q1 2027 and positive rilvegostomig survival data from AstraZeneca.
3mo agoCompugen to present at BTIG Biotechnology Conference 2026
Compugen Ltd. will participate in the virtual BTIG Biotechnology Conference 2026 on July 28-29, 2026, with management presentations and one-on-one meetings. The company's pipeline features COM701, rilvegostomig, and GS-0321, targeting various stages of clinical development. Investors must contact BTIG representatives to schedule meetings, as no event replay will be provided.
3mo agoCompugen presents MAIA-ovarian trial data at ESMO Congress
Compugen Ltd. presented a trial-in-progress poster on the MAIA-ovarian adaptive platform trial of COM701 at the ESMO Gynaecological Cancers Congress 2026. The trial evaluates COM701 as a maintenance therapy in relapsed platinum-sensitive ovarian cancer, with initial data expected by Q1 2027. COM701 has shown consistent responses in platinum-resistant ovarian cancer and is part of Compugen's four clinical-stage immuno-oncology programs.
4mo agoCompugen to present MAIA-ovarian trial data at ESMO 2026
Compugen Ltd. will present a trial-in-progress poster on the Phase 1 MAIA-ovarian study of COM701 at the ESMO Gynaecological Cancers Congress 2026. The poster, presented by Dr. Oladapo Yeku, will evaluate the safety and efficacy of COM701 maintenance treatment in relapsed platinum-sensitive ovarian cancer.
5mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Compugen is now worth
$ 29.55
Resulting in a loss of
$ 70.45 (70.45%)
Note: Past profits do not guarantee future returns.
